Iambic Therapeutics sets IPO terms at $15-$17 per share, targeting up to $806M valuation

Iambic Therapeutics, an Nvidia-backed developer of AI-driven solid tumor therapies, set IPO terms at $15 to $17 per share, offering 9.375 million shares to raise up to $159.4 million at a valuation of up to $806 million, per an SEC filing. ARK Investment and Duquesne Family Office have indicated interest in buying up to $60 million of shares.

Detected & updated continuously · Source: Nebula